Additionally, correlation analysis of immune phenotype scores indicated that in COAD, KIRC, LIHC, LUAD, STAD, THCA, and UCEC, tumor patients with low SF3B6 expression were anticipated to experience improved immunotherapy responses following treatment with CTLA-4 or PD-1 blockade (Van Allen et al., 2015; Hackl et al., 2016). Here, SF3B6 is linked to neoplasm.